
Mahdi Salih

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4582811/publications.pdf Version: 2024-02-01



ΜλΗΡΙ SALIH

#	Article	IF	CITATIONS
1	Urinary extracellular vesicles and the kidney: biomarkers and beyond. American Journal of Physiology - Renal Physiology, 2014, 306, F1251-F1259.	2.7	147
2	The Phosphorylated Sodium Chloride Cotransporter in Urinary Exosomes Is Superior to Prostasin as a Marker for Aldosteronism. Hypertension, 2012, 60, 741-748.	2.7	93
3	Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease. JAMA - Journal of the American Medical Association, 2018, 320, 2010.	7.4	78
4	Update on Controls for Isolation and Quantification Methodology of Extracellular Vesicles Derived from Adipose Tissue Mesenchymal Stem Cells. Frontiers in Immunology, 2014, 5, 525.	4.8	69
5	Rationale and Design of the DIPAK 1 Study: A Randomized Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in Autosomal Dominant Polycystic Kidney Disease. American Journal of Kidney Diseases, 2014, 63, 446-455.	1.9	59
6	A Missense Mutation in the Extracellular Domain of αENaC Causes Liddle Syndrome. Journal of the American Society of Nephrology: JASN, 2017, 28, 3291-3299.	6.1	59
7	Proteomics of Urinary Vesicles Links Plakins and Complement to Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2016, 27, 3079-3092.	6.1	58
8	Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease. Gastroenterology, 2019, 157, 481-491.e7.	1.3	42
9	Noninvasive Assessment of Intra-Abdominal Pressure by Measurement of Abdominal Wall Tension. Journal of Surgical Research, 2011, 171, 240-244.	1.6	39
10	Estimation of Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease. American Journal of Kidney Diseases, 2015, 66, 792-801.	1.9	36
11	An immunoassay for urinary extracellular vesicles. American Journal of Physiology - Renal Physiology, 2016, 310, F796-F801.	2.7	36
12	Urinary extracellular vesicles as markers to assess kidney sodium transport. Current Opinion in Nephrology and Hypertension, 2016, 25, 67-72.	2.0	26
13	Urinary renin-angiotensin markers in polycystic kidney disease. American Journal of Physiology - Renal Physiology, 2017, 313, F874-F881.	2.7	19
14	Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study. Drug Safety, 2017, 40, 153-167.	3.2	16
15	The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease. American Journal of Nephrology, 2017, 46, 239-248.	3.1	15
16	Increased Urinary Extracellular Vesicle Sodium Transporters in Cushing's Syndrome with Hypertension. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2583-2591.	3.6	15
17	Bullous Pemphigoid With a Dual Pattern of Glomerular Immune Complex Disease. American Journal of Kidney Diseases, 2016, 67, 302-306.	1.9	9
18	ldentifying cystogenic paracrine signaling molecules in cyst fluid of patients with polycystic kidney disease. American Journal of Physiology - Renal Physiology, 2019, 316, F204-F213.	2.7	6

#	Article	IF	CITATIONS
19	Effects of Thyroid Hormone on Urinary Concentrating Ability. European Thyroid Journal, 2017, 6, 238-242.	2.4	3
20	Cardiac arrest by inhalation of deodorant spray. BMJ Case Reports, 2018, 2018, bcr-2018-224345.	0.5	3
21	Bleeding risk in patients with autosomal dominant polycystic kidney disease treated with acetylsalicylic acid: implications for prevention of preeclampsia. Journal of Nephrology, 2022, 35, 2425-2427.	2.0	1